LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.53 0.04

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.07

Max

27.74

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.185 57.05
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+49.51% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	49M 1.6B
Ankstesnė atidarymo kaina	27.49
Ankstesnė uždarymo kaina	27.53

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-26 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

2026-03-26 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

2026-03-26 23:35; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard: Confirms Discussions With Brown-Forman

2026-03-26 23:29; UTC

Uždarbis

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

2026-03-26 23:28; UTC

Uždarbis

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

2026-03-26 23:28; UTC

Uždarbis

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

2026-03-26 23:28; UTC

Uždarbis

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

2026-03-26 23:27; UTC

Uždarbis

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

2026-03-26 23:27; UTC

Uždarbis

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

2026-03-26 23:08; UTC

Rinkos pokalbiai

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

2026-03-26 23:04; UTC

Įsigijimai, susijungimai, perėmimai

Pernod in Deal Talks With Brown-Forman -- WSJ

2026-03-26 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

2026-03-26 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

2026-03-26 22:26; UTC

Uždarbis

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

2026-03-26 22:26; UTC

Uždarbis

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

2026-03-26 22:26; UTC

Uždarbis

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

2026-03-26 22:08; UTC

Uždarbis

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

2026-03-26 22:08; UTC

Uždarbis

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

2026-03-26 22:08; UTC

Uždarbis

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

2026-03-26 22:07; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-26 22:07; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

2026-03-26 22:00; UTC

Uždarbis

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

2026-03-26 22:00; UTC

Uždarbis

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

2026-03-26 22:00; UTC

Uždarbis

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

2026-03-26 21:39; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

2026-03-26 21:38; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

49.51% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 49.51%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.